These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35448275)

  • 1. Near-Infrared Transflectance Spectroscopy Discriminates Solutions Containing Two Commercial Formulations of Botulinum Toxin Type A Diluted at Recommended Volumes for Clinical Reconstitution.
    Currà A; Gasbarrone R; Bonifazi G; Serranti S; Fattapposta F; Trompetto C; Marinelli L; Missori P; Lendaro E
    Biosensors (Basel); 2022 Apr; 12(4):. PubMed ID: 35448275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
    Frevert J
    Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AbobotulinumtoxinA (Dysport
    Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the dissociation of botulinum neurotoxin type A complexes.
    Eisele KH; Fink K; Vey M; Taylor HV
    Toxicon; 2011 Mar; 57(4):555-65. PubMed ID: 21195107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the use of botulinum neurotoxins in facial esthetics.
    Flynn TC
    J Cosmet Dermatol; 2012 Mar; 11(1):42-50. PubMed ID: 22360334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near-infrared spectroscopy as a tool for in vivo analysis of human muscles.
    Currà A; Gasbarrone R; Cardillo A; Trompetto C; Fattapposta F; Pierelli F; Missori P; Bonifazi G; Serranti S
    Sci Rep; 2019 Jun; 9(1):8623. PubMed ID: 31197189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical differences between botulinum neurotoxin type A and B.
    Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
    Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of botulinum neurotoxin therapy].
    Mukai Y; Kaji R
    Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SNARE cleavage products generated by formulated botulinum neurotoxin type-a drug products.
    Hunt T; Rupp D; Shimizu G; Tam K; Weidler J; Xie J
    Toxins (Basel); 2010 Aug; 2(8):2198-212. PubMed ID: 22069680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.
    Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1278-84. PubMed ID: 20337830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
    Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
    Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of botulinum toxin immunogenicity.
    Benecke R
    BioDrugs; 2012 Apr; 26(2):e1-9. PubMed ID: 22385408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
    Schulte-Mattler WJ
    CNS Drugs; 2008; 22(9):725-38. PubMed ID: 18698873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of Botulinum Neurotoxin Synthesis and Toxin Complex Formation by Arginine and Glucose in Clostridium botulinum ATCC 3502.
    Fredrick CM; Lin G; Johnson EA
    Appl Environ Microbiol; 2017 Jul; 83(13):. PubMed ID: 28455330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest.
    Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
    J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1285-95. PubMed ID: 20569284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.
    Bryant AM; Cai S; Singh BR
    Toxicon; 2013 Sep; 72():126-32. PubMed ID: 23811077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo non-invasive near-infrared spectroscopy distinguishes normal, post-stroke, and botulinum toxin treated human muscles.
    Currà A; Gasbarrone R; Cardillo A; Fattapposta F; Missori P; Marinelli L; Bonifazi G; Serranti S; Trompetto C
    Sci Rep; 2021 Sep; 11(1):17631. PubMed ID: 34480037
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.